CD4+CD25+FoxP3+ regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease

CD4+CD25+FoxP3+ regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease
复制标题

CD4( )CD25( )FoxP3( ) 调节性 T 细胞抑制活动性疾病患者的结核分枝杆菌免疫。

DOI:
10.1016/j.clim.2006.11.009
复制
发表时间:
2007-04-01
影响因子:
8.6
通讯作者:
Katsanis, Emmanuel
Katsanis, Emmanuel
中科院分区:
医学3区
文献类型:
--
作者:
Chen, Xinchun;Zhou, Boping;Katsanis, Emmanuel

文献摘要

被引文献

相似文献

CD 4(+)CD 25(+)调节性T细胞(Treg)通过下调效应CD 4(+)或CD 8(+)T细胞的功能在预防自身免疫和控制免疫应答中发挥核心作用。Treg在结核分枝杆菌感染和持续性中的作用没有得到充分的记录。因此,本研究旨在确定CD 4(+)CD 25(+)FoxP 3(+)调节性T细胞是否可以调节对人类结核病(TB)的免疫。我们的研究结果表明,在活动性结核病患者的血液或感染部位,CD 4(+)CD 25(+)FoxP 3(+)Treg的数量增加。胸水中CD 4(+)CD 25(+)FoxP 3(+)Treg的表达。体液与局部结核分枝杆菌特异性免疫负相关(p < 0.002)。这些从血液和胸膜液中分离的CD 4(+)CD 25(+)FoxP 3(+)T淋巴细胞能够抑制TB患者中MTB特异性IFN-γ和IL-10的产生。因此,TB患者中CD 4(+)CD 25(+)FoxP 3(+)Treg扩增抑制了M。结核免疫力,因此可能有助于人类结核病的发病机制。(c)2006年爱思唯尔公司All rights reserved.
CD4(+)CD25(+) regulatory T cells (Treg) play a central role in the prevention of autoimmunity and in the control of immune responses by down-regulating the function of effector CD4(+) or CD8(+) T cells. The role of Treg in Mycobacterium tuberculosis infection and persistence is inadequately documented. Therefore, the current study was designed to determine whether CD4(+)CD25(+)FoxP3(+) regulatory T cells may modulate immunity against human tuberculosis (TB). Our results indicate that the number of CD4(+)CD25(+)FoxP3(+) Treg increases in the blood or at the site of infection in active TB patients. The frequency of CD4(+)CD25(+)FoxP3(+) Treg in pleural. fluid inversely correlates with local MTB-specific immunity (p < 0.002). These CD4(+)CD25(+)FoxP3(+) T lymphocytes isolated from the blood and pleural fluid are capable of suppressing MTB-specific IFN-gamma and IL-10 production in TB patients. Therefore, CD4(+)CD25(+)FoxP3(+) Treg expanded in TB patients suppress M. tuberculosis immunity and may therefore contribute to the pathogenesis of human TB. (c) 2006 Elsevier Inc. All rights reserved.